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1. Introduction 
Human respiratory syncytial virus (HRSV) is the leading cause of respiratory failure and 
viral death in infants (Thompson et al., 2003). In HRSV bronchiolitis, plugs of mucus, 
epithelial cell debris, and innate inflammatory cells obstruct the airways leading to 
pulmonary obstruction (Aherne et al., 1970; Lugo and Nahata, 1993). In autopsy lung 
tissues from fatal HRSV disease cases, epithelial damage and mechanical airway 
obstruction are implicated as key features of HRSV pathogenesis (Johnson et al., 2007; 
Welliver et al., 2007). Although laboratory animal models of HRSV pathogenesis have 
been widely used to determine pathogenic mechanisms of HRSV infection, the commonly 
used lab strains of HRSV do not cause airway epithelial cell desquamation, airway mucus 
production, or lung dysfunction in mice (Moore et al., 2009a; Peebles et al., 2001). 
However, some strains of HRSV (e.g. line 19 and clinical isolate A2001/2-20) were shown 
to cause airway mucus expression and lung dysfunction in mice, and clinical isolates can 
cause airway epithelial cell desquamation in mice (Moore et al., 2009a; Stokes et al., 2011). 
The fusion (F) glycoprotein of HRSV strain line 19 was implicated in the mechanism of 
line 19-induced airway mucus (Moore et al., 2009a). Variation in HRSV glycoprotein 
sequence may contribute to disease variation observed clinically. The pathogenesis of 
HRSV is likely due to a combination of host and viral genetic determinants. HRSV strain-
specific virulence in mice facilitates mechanistic studies of HRSV pathogenesis and may 
provide more robust challenge models to test whether vaccines have potential to prevent 
HRSV disease. 
Currently, there are no vaccines for prevention of HRSV disease. There are several obstacles 
to developing successful vaccines for HRSV, including immunological immaturity of 
infants, interference of immunogenicity by maternal Abs, and relatively poor immune 
responses to HRSV. In the 1960s, a formalin-inactivated HRSV (FI-HRSV) vaccine tragically 
resulted in enhanced disease in infants upon natural HRSV infection (Kapikian et al., 1969; 
Kim et al., 1969). Reasons for this may be formation of carbonyl groups on vaccine antigens 
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due to formaldehyde treatment and/or poor Toll-like receptor stimulation by inactivated 
HRSV (Delgado et al., 2009; Moghaddam et al., 2006). Another significant obstacle in vaccine 
development is the lack of stringent challenge animal models. Mice and cotton rats are semi-
permissive for HRSV infection, and species other than the chimpanzee are not particularly 
advantageous over mice and cotton rats (Belshe et al., 1977; Coates and Chanock, 1962; 
Prince et al., 1978; Prince and Porter, 1976). The lack of robust HRSV replication and disease 
in rodents has led to false hopes of vaccine efficacy.  
Bovine RSV (BRSV) is closely related to HRSV and causes a similar disease in young calves. 
The pathogenesis and biology of BRSV are highly similar to HRSV. Successful BRSV 
vaccines are in use, and the vaccinology of BRSV has relevance for HRSV vaccine strategies. 
Another model of HRSV pathogenesis in the natural host is pneumonia virus of mice 
(PVM), a pneumovirus that is a natural pathogen of murids. PVM causes a dose-dependent 
lethal infection in mice with pathologic features resembling severe HRSV bronchiolitis. The 
caveat of using BRSV and PVM models for vaccine advancement is that the antigens are not 
specifically HRSV. Future studies testing HRSV vaccine efficacy would benefit greatly from 
HRSV-BRSV and HRSV-PVM chimeric viruses. Chimeric HRSV-BRSV viruses have been 
generated by RSV reverse genetics, and additional chimeras could be useful as robust 
challenge strains (Buchholz et al., 2000). Such a chimeric approach is taken in the HIV and 
influenza vaccine fields to overcome limits on host restriction. 
2. Pathologic features of HRSV, BRSV, and PVM in their natural hosts 
2.1 Pathologic features of natural HRSV infection in infants 
Pathologic features of HRSV infection have not been extensively characterized because 
few reports have described autopsy findings in immunocompetent humans infected with 
HRSV. Furthermore, HRSV-infected patients who die often do so after days to weeks of 
intensive therapy which may include mechanical ventilation, oxygen therapy, and other 
interventions which can superimpose non-HRSV induced pathology (DeVincenzo, 2007). 
However, an informative report described lesions in an HRSV-infected child who died in 
an automobile accident, along with lesions from 3 archived cases from 1931-1949, prior to 
the initiation of modern intensive care practices (Johnson et al., 2007). 
Immunohistochemical (IHC) staining revealed viral antigen in bronchiolar epithelial cells, 
including ciliated cells. Intrabronchiolar syncytia were present in one patient. Viral 
antigen was also identified in type I and type II alveolar epithelial cells. Debris in airways 
consisted of fibrin and mucus along with sloughed epithelial cells and macrophages that 
stained positive for HRSV. Peribronchiolar and periarteriolar inflammation was 
characterized by mononuclear and lymphocytic infiltration. Organized lymphoid 
aggregates were often present, and bronchial arteries were congested. Neutrophils could 
be seen migrating into bronchioles and along the bronchiolar epithelium. Eosinophils 
were occasionally present in the peribronchiolar infiltrate. In the pulmonary parenchyma, 
interstitial inflammation was present, with marked vascular congestion. Three patients 
had intraalveolar leakage of fibrin with infiltration of macrophages and occasional 
neutrophils. One patient had severe pneumonitis with rare focal necrosis and 
hemorrhage. In these children with natural HRSV infection, bronchiolar-associated 
lymphoid tissue (BALT) was prominent and often hyperplastic (Johnson et al., 2007). 
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Immunohistochemical staining to characterize the phenotype of infiltrating cells was 
undertaken in one case. In this patient, the BALT consisted largely of CD20+ B cells with 
some CD3+ T cells and CD68+ monocytes. In contrast, CD3+ T cells were most prominent 
in the spaces between pulmonary arterioles and small distal airways; they were also 
found in the bronchiolar epithelium and in the alveolar interstitium. Despite the presence 
of T and B cells, the prominent pathologic changes of fatal HRSV infection were 
widespread viral antigen in airway and alveolar epithelia and mechanical obstruction of 
airways. 
A second report describing histopathologic changes in infants with fatal HRSV-induced 
disease who were not subjected to prolonged mechanical ventilation or antiviral or anti-
inflammatory therapy revealed similar findings to those in of Johnson et al. (Welliver et 
al., 2007). In tissues from nine patients who died due to severe lower respiratory tract 
infection and which were positive on IHC staining for HRSV, the terminal bronchioles 
were plugged with sloughed epithelial cells with abundant viral antigen identified by 
IHC. Bronchiolar walls were infiltrated with neutrophils and macrophages. As compared 
to tissues from children infected with influenza, HRSV-induced bronchiolar epithelial 
damage seemed much greater, and the amount of viral antigen present was increased. In 
contrast to the single case in which T cell subsets were evaluated by Johnson et al., CD4+ 
or CD8+ cells were infrequently identified by IHC staining of bronchioles and alveoli 
(Welliver et al., 2007). Staining for CD16 was used to identify neutrophils and 
macrophages and found to be extensive in HRSV-infected children. Staining for the 
apoptosis marker caspase 3 was strongly positive in bronchiolar epithelial cells. The 
conclusion of Welliver et al. was that children dying of severe acute HRSV infection 
suffered from bronchiolar obstruction due to widespread death and sloughing of 
epithelial cells. An excessive immune response mediated by T cells did not seem to be 
involved because of relatively few T cells found in these tissues. Although immune 
responses play important roles in HRSV pathogenesis, these two pathology studies taken 
together show that severe, unchecked HRSV disease in infants is a pulmonary disease 
associated with virus-induced epithelial damage leading to airway obstruction and not 
associated with immunopathology per se, e.g. excessive T cells or cytokine storm 
(DeVincenzo, 2007; Johnson et al., 2007; Welliver et al., 2007). 
2.2 Pathologic features of BRSV infection in calves 
Pathologic changes in the lungs of calves that die or are euthanized due to natural BRSV 
infection share many similarities with those described for children with fatal HRSV 
infection. Bronchitis and bronchiolitis with necrosis and sometimes hyperplasia of the 
bronchiolar epithelium is present, with lumina of bronchioles containing sloughed 
epithelial cells, neutrophils, mononuclear cells, and proteinaceous debris (Bryson et al., 
1983; Elazhary et al., 1982; Pirie et al., 1981). Viral antigen is identified in bronchiolar and 
alveolar epithelial cells by IHC. Mononuclear cells are present in the bronchiolar lamina 
propria and surrounding bronchioles (Bryson et al., 1983; Pirie et al., 1981). Alveolar 
inflammation is also present, with neutrophils, monocytes, and macrophages in alveolar 
lumina and in the interstitium. Edema is present in alveolar lumina as well as 
interstitially, sometimes with hemorrhage and emphysema. Syncytia in bronchiolar and 
alveolar lumina are frequent (Bryson et al., 1983; Pirie et al., 1981). From these reports it 
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appears that neutrophils play a larger role in the response to BRSV, although this may be 
in part due to frequent co-infection with mycoplasmas or other bacterial respiratory 
pathogens in calves in some reports (Bryson et al., 1983; Pirie et al., 1981). However, 
experimentally induced cases of BRSV infection where bacterial co-infection was not 
present were also characterized by bronchiolar epithelial necrosis and sloughing, with 
infiltration of neutrophils, lymphocytes, and mononuclear cells into bronchiolar and 
alveolar lumina (Bryson et al., 1983; McNulty et al., 1983). As noted for fatal HRSV, death 
of BRSV-infected bronchiolar and alveolar epithelial cells is associated with apoptosis 
(Viuff et al., 2002; Welliver et al., 2007). 
As for HRSV, there is evidence that immune responses to BRSV infection can contribute to 
disease severity in at least some individuals. Although there are relatively few detailed 
studies of pathogenesis of naturally occurring disease due to BRSV infection, research by 
two different groups indicated a role for mast cell degranulation and mediator release in 
disease severity (Jolly et al., 2004; Kimman et al., 1989b). Unfortunately neither of these 
groups measured BRSV-specific IgE in affected calves so it is not clear if mast cell 
degranulation was triggered by virus-specific IgE or through other mechanisms. Other 
research has shown that BRSV-specific IgE concentration in blood or pulmonary efferent 
lymph can be strongly correlated with disease severity in BRSV infection, and that 
transcription of IL-4 mRNA is associated with IgE production (Gershwin et al., 2000). 
2.3 Pathologic features of experimental PVM infection of mice 
Like HRSV and BRSV, PVM is a member of the genus Pneumovirus within the family 
Paramyxoviridae. The PVM genome has 29-62% nucleotide identity to HRSV and BRSV, 
which are closely related to each other (Krempl et al., 2005). PVM is a natural respiratory 
pathogen of murids, and laboratory mouse strains are highly susceptible to experimental 
PVM infection (Rosenberg et al., 2005). PVM challenge of mice showed that changes in 
bronchial epithelial cells were evident as early as day 1 post-infection and were 
characterized by granular changes in the cytoplasm with lifting and stripping of the 
bronchial epithelium and shedding of cellular debris into bronchial lumina (Carthew and 
Sparrow, 1980). Plugs of cellular debris and neutrophils were evident by day 4 post-
infection, as were severe alveolar congestion and edema, with infiltration of neutrophils and 
macrophages into alveolar spaces and the interstitium. In contrast to HRSV and BRSV, 
syncytial cells were not described in airways or alveoli. By day 7 post-infection alveolar 
spaces were filled with neutrophils, macrophages, and lymphocytes. IHC staining for PVM 
revealed virus in bronchial epithelial cells by day 2 post-infection, and virus in alveolar 
epithelial cells by day 4 post-infection. Virus was no longer evident by IHC staining after 
day 7 post-infection. As has been noted for BRSV (Gershwin et al., 1998) and HRSV (Stokes 
et al., 2011), pathologic changes in mice infected with PVM depend on the virulence of the 
challenge isolate; challenge of mice with the virulent strain J3666 induces more severe 
pathology than does challenge with strain 15 (Domachowske et al., 2002). Overall, the 
histopathology of severe HRSV, BRSV, and PVM infection in the natural host show striking 
similarities in 1) viral tropism for airway and alveolar epithelial cells, 2) airway epithelial 
desquamation, 3) obstruction of airways with mixtures of mucus, fibrin, and cells (epithelial 
debris and inflammatory cells), and 4) prominent neutrophil and macrophage inflammation 
in bronchiolar, alveolar, and interstitial spaces. 
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3. Animal models of HRSV pathogenesis 
3.1 Mouse models of HRSV infection: Different HRSV strains 
3.1.1 HRSV A2 strain mouse model 
Mice are semi-permissive for HRSV replication, and BALB/c mice are one of the more 
susceptible strains (Prince et al., 1979). The A2 and Long strains are antigenic subgroup A 
reference strains. A2 was isolated in Australia in 1961, and Long was isolated in Baltimore in 
1956. A hallmark of experimental pulmonary HRSV infection of mice is mononuclear cell 
lung infiltrates. The A2 strain has been used to elucidate roles T cells play in HRSV 
clearance, immunopathology, and immune modulation. Intranasal A2 strain infection of 
BALB/c mice induces IFN- and T cell-mediated clearance and immunopathology. Viral 
titers peak approximately 4 days post-infection and lymphocytic inflammation peaks one 
week post-infection. The peak lung T cell response of BALB/c mice to A2 infection is 6-12 
days post-infection, and IFN--expressing CD8+ T cells peak before HRSV-specific CD8+ T 
cells (Chang and Braciale, 2002; Chang et al., 2001; Hussell and Openshaw, 1998). CD4+ and 
CD8+ T cells exacerbate A2-induced illness and mediate virus clearance (Graham et al., 
1991). Foxp3+ CD4 T cells (Tregs) coordinate CD8+ T cell recruitment, downregulate CD8+ T 
cell TNF-ǂ production, and limit disease severity (ruffled fur) in HRSV A2-infected BALB/c 
mice (Fulton et al., 2010). The A2 strain has been used to define CD8+ T cell responses to 
specific HRSV epitopes (Lee et al., 2007; Ruckwardt et al., 2010). Although A2 infection of 
mice does not replicate human disease, the strain is important in the field as a reference 
strain, the basis of current reverse genetics systems, for HRSV protein structure studies, and 
for vaccine development (Collins et al., 1995; Jin et al., 1998; McLellan et al., 2011).  
A2 HRSV inhibits T cell function in mice. During the CTL response to HRSV, approximately 
half of HRSV-specific CD8+ T cells in the lungs of BALB/c mice produce IFN-, compared to 
influenza virus infection where nearly all influenza-specific CD8+ T cells in the lung are IFN-
+ (Chang and Braciale, 2002). These data are in agreement with HRSV suppression of T cell 
proliferation in vitro (Preston et al., 1992, 1995; Roberts et al., 1986). HRSV inhibition of T cell 
responses may be an important reason why HRSV does not confer adequate immunity. 
3.1.2 HRSV strain line 19 infection of mice 
RSV strain line 19 is an antigenic subgroup A strain derived from a RSV clinical isolate 
obtained at the University of Michigan in 1967 (Herlocher et al., 1999). “Line 19” has been 
used as the name of a HRSV strain used by the Lukacs lab at the University of Michigan and 
other groups (Lukacs et al., 2006). The genome sequence of this line 19 was reported, and it 
is highly similar to the Long strain of HRSV (Moore et al., 2009a). The lack of nucleotide 
differences between line 19 and Long, particularly in the hypervariable regions of the G 
gene an in intergenic regions, raises the question of whether this line 19 is a passage variant 
of the Long strain. It may be that line 19 and Long derive from the same clinical isolate or 
nearly identical isolates circulating in Baltimore in 1956 (Long) and Ann Arbor in 1967 (line 
19). However, it is interesting that the Long strain was adapted to mice by serial passage in 
the brains of suckling mice in the 1960s at the University of Michigan, and mouse passage 
number 19 in this study was noted as virulent (Cavallaro and Maassab, 1966). Whether 
currently used line 19 represents the 1967 Michigan clinical isolate (Herlocher et al., 1999) or 
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mouse-adapted Long (Cavallaro and Maassab, 1966) is not as important as the fact that line 
19 is a good tool to study HRSV-induced pulmonary pathophysiology in mouse models. 
The pathogenesis of HRSV line 19 differs from the pathogenesis of HRSV A2 (Lukacs et al., 
2006). Similar to A2, line 19 induces high levels of IFN- in the lung (Lukacs et al., 2006; 
Tekkanat et al., 2001). A2 replicates in HEp-2 cells and in the lungs of BALB/c mice to 
higher titers than line 19 (Lukacs et al., 2006). In contrast to A2, line 19 infection of BALB/c 
mice increases IL-13 levels in the lungs (Lukacs et al., 2006; Tekkanat et al., 2001). Line 19 
infection causes mucus production and airway hyperresponsiveness (AHR) in BALB/c 
mice, whereas A2 does not (Lukacs et al., 2006; Tekkanat et al., 2001). Line 19 infection-
induced mucus and AHR are IL-13-dependent and STAT6-dependent (Lukacs et al., 2006; 
Tekkanat et al., 2001). Line 19-induced AHR is ameliorated by neutralization of the 
chemokine CCL5 (RANTES), and CCL5 production in the lung was shown to be IL-13-
dependent in line 19-infected mice (Tekkanat et al., 2002).  
More recently, the Lukacs group has identified a role for the cytokine IL-17 in RSV 
pathogenesis. IL-17 is produced by CD4+ TH17 cells and has been associated with bacterial 
infections, neutrophilic inflammation, and pro-allergic airway inflammation (Alcorn et al., 
2010). Mice deficient in toll-like receptor 7 (TLR7), an innate immune system molecule 
recognizing single stranded RNA in endosomes (a common feature of virus infection), had 
greater lung IL-17 levels than wild-type mice after HRSV line 19 infection, and 
neutralization of IL-17 in line 19-infected TLR7-deficient mice reduced airway mucin 
expression (Lukacs et al., 2010). Bone marrow-derived dendritic cells (DCs) from TLR7-
deficient mice expressed higher levels of IL-23 (an IL-17-promoting cytokine) in response to 
line 19 infection in vitro than wild-type DCs (Lukacs et al., 2010). These data suggest that the 
innate TLR response to HRSV restricts a pathogenic IL-17 response. IL-17 was found in 
tracheal aspirates of infants with severe RSV illness, and line 19-infected IL-17-deficient mice 
had less airway mucin expression than control mice (Mukherjee et al., 2011). These studies 
indicate that TH17-type inflammation contributes to pulmonary mucus in the pathogenesis 
of HRSV. Previous reports implicated IL-4 and TH2-type lung inflammation in severe HRSV 
disease, although this association has not been consistent (Brandenburg et al., 2000; Garofalo 
et al., 2001; Legg et al., 2003; Roman et al., 1997). The overall picture from the literature is 
that the balance of canonical TH1 (IFN-Ǆ) and TH2 (IL-4) cytokines does not correlate with 
HRSV disease severity. The findings from the Lukacs group suggest that IL-17 (TH17) should 
be considered in assessing the role of host immune responses in HRSV pathogenesis. 
3.1.3 HRSV clinical isolate infection of mice 
HRSV is an RNA virus with a mutation rate of 3.3 × 10-3 substitutions/site/year, equivalent 
to human influenza A virus (Jenkins et al., 2002). The A2 and Long reference HRSV strains 
have been passaged extensively in vitro and do not fully represent circulating HRSV. Viral 
disease depends exquisitely on viral strains. Small changes in viral gene sequences can have 
a large impact on pathogenesis. For example, elevated virulence of 1918 and avian influenza 
strains hinges on few amino acids differences (Hatta et al., 2001; Tumpey et al., 2005; Yu et 
al., 2008). Virulence in animal models of virus infection invariably depends on viral strains, 
across virus families (Ahmed and Oldstone, 1988; Borisevich et al., 2006). Relatively minor 
differences between viral strains also play important roles in complex human diseases. 
Examples include papillomavirus types (e.g. HPV-16) strongly associated with cervical 
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cancer and hepatitis c virus genotypes associated with acute or persistent infection (Howley 
et al., 1989; Lehmann et al., 2004). Recently, a group of rhinoviruses (RV group C) was 
associated with half of all RV hospitalizations in young children, especially for asthma 
exacerbation (Miller et al., 2009).  
HRSV clinical isolate strain 13018-8 was used to study the effects of HRSV on mouse DCs 
(Gonzalez et al., 2008). This HRSV caused maturation of mouse DCs, but the DCs were then 
unable to activate antigen-specific T cells in vitro, regardless of the antigen specificity 
(Gonzalez et al., 2008). The authors did not compare strain 13018-08 to a laboratory HRSV 
strain. The findings advance a mechanism (inhibition of DC-T cells immunological synapse 
formation) for HRSV suppression of T cell function (Gonzalez et al., 2008). HRSV clinical 
isolates exhibit varied pathogenesis phenotypes in BALB/c mice (Stokes et al., 2011). Out of 
six antigenic subgroup A isolates tested, three increased IL-13 levels in the lungs of BALB/c 
mice, and two (A2001/2-20 and A1997/12-35) induced greater IL-13 levels and weight loss 
than HRSV line 19 (Stokes et al., 2011). The clinical isolates had higher lung viral load than 
A2 and line 19 one day post-infection, viral antigen at this time point was localized to the 
bronchiolar epithelium, and there was corresponding histologic evidence of damage to the 
bronchiolar epithelium in mice infected with clinical isolates (Stokes et al., 2011). HRSV 
A2001/2-20 increased airway mucus expression and increased breathing effort in BALB/c 
mice whereas A2001/3-12 did not despite these two isolates exhibiting equivalent lung viral 
loads over a time course (Stokes et al., 2011). As with line 19, airway mucus induced in 
BALB/c mice by A2001/2-20 was IL-13-dependent (Stokes et al., 2011; Tekkanat et al., 2001).  
3.2 HRSV infection of cotton rats 
The cotton rat Sigmodon hispidus is one of the best small animal models of HRSV infection. 
Whereas infant but not adult ferrets are susceptible to HRSV, cotton rats are susceptible to 
HRSV infection throughout life (Prince et al., 1978; Prince and Porter, 1976). The virtues of 
cotton rats for HRSV research were recently reviewed and include approximately 100-fold 
more permissiveness to HRSV infection than mice (Boukhvalova et al., 2009). A 
disadvantage is that there are few reagents available for the cotton rats relative to mice. 
Cotton rats are susceptible to upper and lower respiratory tract infection with HRSV (Prince 
et al., 1978). HRSV replicated to relatively high titers in the nasal turbinates and lungs of 
naïve cotton rats (Prince et al., 1990; Prince et al., 1986; Prince et al., 1978). HRSV antigen 
was detected in nasal, bronchial, and bronchiolar epithelial cells (Prince et al., 1978). HRSV 
infection caused proliferative rhinitis, bronchiolitis, and the pulmonary infiltration of 
lymphocytes and neutrophils (Prince et al., 1986; Prince et al., 1978). The cotton rat model 
was used to study the Ab-mediated clearance of HRSV, and the data indicate that IgG-
mediated HRSV clearance does not require antibody-dependent cellular cytotoxicity or 
complement (Prince et al., 1990). HRSV infection increased cotton rat lung mRNA steady 
state levels of RANTES, IP-10, MIP-1, GRO, IFN-, IFN-, IL-6, IL-10, and TNF- (Blanco et 
al., 2002). GRO is a homolog of the human IL-8 chemokine and functions to recruit 
neutrophils. IP-10 is a chemokine that is known to attract T cells and NK cells. In cotton rat 
treated with a TLR3 agonist then infected with HRSV, it was shown that type I IFN 
responses can augment lung inflammation in this model (Boukhvalova et al., 2010). 
An interesting recent study performed with HRSV Long strain showed that HRSV treatment 
of mouse peritoneal and alveolar macrophages induces these macrophages to become 
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alternatively activated to express TH2 cytokines IL-4 and IL-13, and infection of cotton rats 
with HRSV Long increased markers of alternatively activated macrophages (Shirey et al., 
2010). Although the role of TH2 cytokines in HRSV pathogenesis has been controversial, 
most studies have focused on a T cell source of these cytokines, e.g. by stimulation of patient 
peripheral blood mononuclear cells (PBMCs). Basophils can produce IL-4 in HRSV-infected 
mice, but these cells are rare (Moore et al., 2009b). The finding that macrophages can express 
TH2 cytokines in response to HRSV (Shirey et al., 2010) is potentially very important because 
TH2 cytokines (especially mucus-associated IL-13) are thought to contribute to HRSV disease 
and, as noted above, HRSV, BRSV, and PVM lung pathology in the natural host is 
characterized by prominent macrophage accumulation in bronchiolar and alveolar spaces.  
3.3 Neonatal lamb model of HRSV infection 
Neonatal (2-3 days of age) lambs were given a high dose of intrabronchial HRSV A2 
infection (Olivier et al., 2009). Clinically, the lambs exhibited fever and, and some had a 
moderate cough (Olivier et al., 2009). Histopathology showed suppurative bronchiolitis 
with epithelial desquamation and cellular debris and neutrophils in airway lumina. HRSV 
antigen was detected by IHC, and it was fairly extensive in the bronchiolar epithelium 
and in alveolar regions where syncytia were evident (Olivier et al., 2009). In a second 
study from the Ackermann group, immune responses of newborn lambs infected with 
HRSV A2 were examined (Sow et al., 2011). A2 infection caused lung accumulation of 
neutrophils, macrophages, and CD4+ and CD8+ cells (Sow et al., 2011). Interestingly, IFN-
ǂ was not detected by RT-PCR, and lung IFN-ǃ levels were actually lower in infected 
animals than in mock-infected animals, suggesting that HRSV suppressed type I IFN 
responses in this model (Sow et al., 2011). Cytokines and chemokines increased by HRSV 
A2 infection in the lungs of newborns lambs were TNF-ǂ (day 3 post-infection), IL-10 (day 
3 post-infection), IFN-Ǆ (day 6 post-infection), IL-8 (day 6 post-infection), and MCP-1 (in 
macrophage-enriched laser capture microdissection regions day 6 post-infection). RT-PCR 
assays for IL-4, IL-13, and IL-17 mRNA levels gave results below the limit of detection 
(Sow et al., 2011). As in the pathology study of severe HRSV disease in infants noted 
above, there was evidence of widespread apoptosis in lungs of HRSV A2-infected 
newborn lambs (Sow et al., 2011; Welliver et al., 2007). New lambs appear to model HRSV 
disease closely, although PAS staining was not reported nor mucus evident in the airways 
in the histology micrographs. 
3.4 Non-human primate models of HRSV infection 
HRSV was originally isolated from chimpanzees, and this species is the only non-human 
primate model for HRSV that provides significantly greater permissivity than cotton rats. 
Young chimpanzees are productively infected with HRSV and exhibit upper respiratory 
tract illness, but adult squirrel monkeys, newborn rhesus monkeys, and infant cebus 
monkeys shed low virus levels and do not show clinical disease (Belshe et al., 1977). 
Bonnet monkeys can be infected with HRSV. However, a high HRSV dose resulted in 
viral titers similar to those seen in cotton rats, and the infected monkeys did not have 
clinical disease (Simoes et al., 1999). Chimpanzees can be valuable for HRSV vaccine 
evaluation (Teng et al., 2000). However high cost, regulatory issues, and genetic 
variability are major constraints. 
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3.5 Primary cell culture models of HRSV infection 
Although cell and tissue culture systems lack an intact immune system, they can provide 
information about virus-host interactions, including immune pathways. Human airway 
epithelial (HAE) cells derived from surgery can be cultured at an air-liquid interface to 
produce a differentiated, polarized mucociliary epithelium. In this system, HRSV 
specifically infects ciliated epithelial cells via the apical membrane (Zhang et al., 2002). 
HRSV was shed from the apical surface, and there was no cytopathic effect (CPE) (Zhang et 
al., 2002). However, it is possible that loosely adherent syncytia were washed off the apical 
surface in collection of supernatants for viral titration. Sendai virus (a paramyxovirus) 
readily causes syncytia in an elegant HAE system of well-differentiated pediatric bronchial 
epithelial cells (WD-PBEC) (Villenave et al., 2010). In non-polarized monolayers of primary 
pediatric bronchial epithelial cells, HRSV A2 replicated to higher titers and caused greater 
CPE than HRSV clinical isolates (Villenave et al., 2011). HRSV infection of primary epithelial 
cells results in the secretion of the chemokine IL-8 that is involved in neutrophil recruitment 
(Mellow et al., 2004; Villenave et al., 2011). In addition to epithelial cells, primary immune 
cells provide information about HRSV-host interactions. HRSV infects human monocyte-
derived immature DCs inefficiently (Le Nouen et al., 2009). In a co-culture system of human 
DCs and T cells, it was shown that the HRSV NS1 protein (a type I IFN antagonist) 
suppressed CD8 T cell activation and proliferation, skews the CD4 T cell phenotype to TH2-
type responses, and suppresses markers of DC maturation (Munir et al., 2011). Also in this 
DC-T cell co-culture system, comparison of influenza A virus, human parainfluenzavirus 
type 3 (HPIV3), HRSV A2, and human metapneumovirus (HMPV) revealed that HRSV and 
HMPV uniquely fail to stimulate CCR7 expression by DC, resulted in impaired DC 
migration (Le Nouen et al., 2011). DCs are key for initiating adaptive immune responses in 
lymph nodes. Therefore, HRSV suppression of DC migration may underlie the relatively 
(compared to influenza viruses) poor immunity elicited by HRSV infection.  
4. Challenges to HRSV vaccine development 
4.1 Inhibition of pediatrics vaccines by maternal antibodies 
Since hospitalization rates for HRSV infected children peak at 2 to 6 months of age, 
immunization for this age will be required for the prevention of severe HRSV disease (Boyce 
et al., 2000; Shay et al., 1999). However, there are several hurdles to develop HRSV vaccine 
in infants. One of the major obstacles is the inhibitory influence of maternal antibody 
(MatAb) on neonatal immunization (Crowe, 1998; Siegrist, 2003). Evidence of MatAb-
mediated immune suppression in human studies has been well described in other infections 
such as measles, parainfluenza viruses (PIV) and influenza viruses (Albrecht et al., 1977; 
Crowe, 1998). Although underlying mechanisms by which MatAb suppresses infant 
responses to vaccination are not fully defined, possible hypothesized mechanisms are 1) Fc 
dependent phagocytosis, 2) neutralization of live viral vaccines, and 3) epitope masking by 
MatAb. First, inhibitory influence by MatAb could be mediated by Fc-dependent 
phagocytosis. The internalization of MatAb and antigen complex by antigen-presenting cells 
(APC) results in the inhibition of infant B cells in both human and mice. However, a study 
using FcR knockout mice demonstrated that the existence of FcR-independent inhibitory 
mechanisms (Karlsson et al., 1999). Next, the hypothesis that MatAb neutralizes the live 
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viral vaccine has been widely believed (Albrecht et al., 1977). MatAb can inhibit viral 
replication of live attenuated HRSV in mice (Crowe, 2001a). Notably, MatAb does not affect 
the induction of T cell responses to HRSV or measles virus (Crowe et al., 2001; Gans et al., 
1999). Lastly, as mentioned above, the hypothesis of B cell epitope specific masking has been 
postulated based on the possibility of the existence of an Fc-independent mechanism. 
Evidence of MatAb epitope masking is that MatAb to the V3 loop of HIV gp120 inhibited 
induction of Ab responses only to V3 but not to other epitopes (Jelonek et al., 1996). Similar 
results were observed in human infants (Kurikka et al., 1996; Nohynek et al., 1999). Several 
strategies should be considered to overcome the obstacles mediated by MatAb to effective 
vaccination of infants. First, novel immunization routes can be tested to determine whether 
vaccination route can modulate susceptibility to inhibition by MatAb. Second, infant T cell 
vaccines can be considered. According to previous observations, MatAb inhibits infant Ab 
responses but not infant T cell responses (Gans et al., 1999; Pabst et al., 1999).) 
4.2 Non-durable immunity induced by natural HRSV infection 
RSV elicits innate and adaptive immune responses that fail to establish long-lasting 
immunity because reinfection occurs throughout life (Collins et al., 2006). HRSV 
neutralizing Ab (nAb) can prevent RSV infection. Serum nAb titer is the best immune 
correlate of protection in humans, and a serum nAb titer of 1:300 is a benchmark for 
protection (Collins et al., 2006; Group, 1998; Prince et al., 1985). The RSV G and F proteins 
are virion surface glycoprotein spikes and the only known targets of RSV nAbs (Collins et 
al., 2006). Local secretory IgA also correlates with protection from RSV disease (Collins et al., 
2006; Walsh, 1993). However, natural RSV infection is poorly immunogenic in children < 6 
months old. Rates of detectable neutralizing Ab responses to natural infection in this age 
group are 50-75% (Brandenburg et al., 1997; Murphy et al., 1986a; Wagner et al., 1989; 
Welliver et al., 1980). In infants, immunological immaturity and suppression of immune 
responses by matAbs contribute to poor immunogenicity (Crowe, 2001c; Crowe and 
Williams, 2003). Seronegative infants and children can mount strong anti-G and anti-F Ab 
responses, although neonates produce poor Ab responses perhaps due to fewer somatic 
hypermutations in Ab genes (Shinoff et al., 2008; Weitkamp et al., 2005; Williams et al., 2009; 
Wright et al., 2000). Immunity to HRSV in adults is also non-durable. A striking example is a 
study in which HRSV nAbs were titrated in 457 cord blood samples in the Danish National 
Birth Cohort (DNBC) from 1998 to 2003 in order to study the temporal relationship between 
maternally-derived nAb and the seasonality of HRSV infant hospitalizations (Stensballe et 
al., 2009). The titer of nAb in cord blood oscillated. NAb titers were highest a few months 
after the annual HRSV winter epidemic and lowest just before the HRSV season, suggesting 
a cyclic model in which nAb titers in mothers (which are transferred to infants) wane after 
six months contributing to the next epidemic which boosts nAb titers for another six 
months. (Stensballe et al., 2009). In addition to low and non-durable Ab responses, the 
cellular immune response to HRSV infection is inhibited. As discussed above, HRSV inhibits 
T cell function in mice and in human DC-T cell co-cultures, and the HRSV NS1 protein (IFN 
antagonist) was implicated in suppression of T cell activation (Chang and Braciale, 2002; Le 
Nouen et al., 2011; Munir et al., 2011). Suboptimal immunity to HRSV infection is important 
for vaccine development because it implies that intranasal delivery of a live attenuated 
HRSV will not be effective. The degrees to which 1) matAb in infants, 2) immature immune 
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system in infants, 3) immune modulation by HRSV, and 4) lack of optimal assays to measure 
HRSV immune responses and protection in patients contribute to the interpretation of poor 
immunogenicity in the vaccine target population needs to be elucidated. 
4.3 Instability of live attenuated HRSV vaccines 
Live HRSV vaccine candidates with attenuating mutations have been created by traditional 
methods of cold-adaptation (cold passage, cp) and chemical mutagenesis to yield 
temperature-sensitive (ts) HRSV mutants that replicate at temperatures  similar to the upper 
respiratory tract but not at higher temperatures (Collins and Murphy, 2005). These 
mutations were defined by sequencing, and mutant HRSV strains that harbor cpts mutations 
have been generated by reverse genetics and tested as vaccine candidates. Leading live 
attenuated HRSV vaccine candidates and HRSV vaccine development have been reviewed 
(Collins and Murphy, 2005; Crowe, 2001b; Graham, 2011). Attenuating mutations are not 
necessarily additive, but addition of attenuating mutations into an already attenuated RSV 
vaccine candidate can decrease the rate of reversion to less attenuated genotypes, thereby 
increasing “genetic stability” (Collins and Murphy, 2005). A leading vaccine candidate 
(rA2cp248/404/1030ΔSH) was adequately attenuated in infants, but one third of isolates 
from nasal washes of vaccinees contained HRSV with loss of attenuation, evidence of 
reversion to wild-type, confirmed by sequence analysis (Karron et al., 2005). A strategy was 
explored to stabilize the “248” point mutation in the viral polymerase gene by mutagenizing 
the codon to encode an attenuating mutation with more than one nucleotide difference from 
the wild type (Luongo et al., 2009), as more nucleotide differences per degree of attenuation 
will be less likely to revert to wild-type. However, in the case of the 248 point mutation, this 
was not possible due to sequence constraints (Luongo et al., 2009). Instability of live vaccine 
strains has been an issue with poliovirus. Codon “de-optimization” of poliovirus by titration 
of CpG dinucleotides into the genome has produced viruses with tunable fitness, a strategy 
that may work for HRSV (Burns et al., 2009). 
4.4 Formalin-inactivated HRSV vaccination 
HRSV was discovered in 1956 (Chanock et al., 1957; Chanock, 1956). Once HRSV was 
recognized to be a common cause of upper and lower respiratory tract disease in infants and 
children, efforts were undertaken to develop a vaccine. In 1966, a formalin-inactivated 
whole virus RSV vaccine adsorbed to alum adjuvant (FI-HRSV) was administered to 
children (Kapikian et al., 1969; Kim et al., 1969). The following winter, compared to 
unvaccinated children, those who received FI-HRSV had a higher incidence of 
hospitalization and greater LRI severity due to HRSV (Kapikian et al., 1969; Kim et al., 1969). 
Two FI-HRSV-immunized infants died, and HRSV was recovered from lung sections (Kim 
et al., 1969). FI-HRSV enhanced respiratory disease (ERD) can be recapitulated using mice, 
cotton rats, calves, and non-human primates by FI-HRSV vaccination and HRSV challenge 
(Delgado et al., 2009; Gershwin et al., 1998; Graham et al., 1993; Johnson et al., 2004a; 
Moghaddam et al., 2006; Prince et al., 1986) Key features of FI-HRSV ERD are 1) failure to 
protect against HRSV replication, 2) an Ab response lacking in virus-neutralizing Abs, 3) a 
poor HRSV-specific CD8+ T cell response, 4) an immunopathologic TH2 immune response, 
and 5) immune complex deposition (Graham et al., 1993; Murphy and Walsh, 1988; Olson 
and Varga, 2007; Polack et al., 2002). HRSV G protein is implicated in ERD because priming 
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with HRSV G-expressing vaccinia virus (vac-G) followed by HRSV challenge results in ERD 
whereas vac-F primes for protection (Srikiatkhachorn and Braciale, 1997). Vac-G-mediated 
ERD and FI-HRSV ERD act through different immune mechanisms, and G is not required 
for FI-RSV ERD (Johnson et al., 2004a; Johnson et al., 2004b). Nevertheless, vac-G studies 
revealed the potential for G to cause ERD. What causes FI-HRSV ERD? One hypothesis is 
that formalin disrupts antigenicity. Formalin causes formation of reactive carbonyl groups 
on HRSV proteins, and chemical reduction of these groups reduces FI-HRSV ERD 
(Moghaddam et al., 2006). Another mechanism invokes nonfunctional Ab responses in the 
absence of appropriate adjuvant, particularly TLR agonists. Co-formulation of ERD-causing 
inactivated HRSV vaccines with CpG ODN (a TLR9 agonist), MPL (a TLR4 agonist), and 
other adjuvants ameliorates ERD (Boukhvalova et al., 2006; Delgado et al., 2009; Mapletoft et 
al., 2008; Oumouna et al., 2005).  
It appears that vaccination with FI-HRSV induced excessive activation of TH2 cells, as 
measured by increased expression of cytokines including IL-4, IL-5, and IL-10, and relatively 
decreased expression of cytokines including IFN-Ǆ and IL-2, by circulating or tissue 
lymphocytes following HRSV infection. The strong TH2 response to FI-HRSV may suppress 
the anti-viral TH1 response and development of cytotoxic T lymphocytes (CTL), mechanisms 
that limit viral replication in the normal response to HRSV infection. Immune pathways 
activated by TH2 cells likely also contributed to the influx of eosinophils seen in the lungs of 
the two children who died as a result of FI-HRSV enhanced disease, which may have 
contributed to the excessive inflammatory response. However, utilization of eosinophil-
deficient mice revealed that eosinophils are not required for ERD in mice induced by either 
vac-G and HRSV challenge or FI-PVM antigens and PVM challenge (Castilow et al., 2008; 
Percopo et al., 2009). 
4.5 Extrapolation of vaccine efficacy from animal models 
One of the challenges in determining how FI-HRSV caused ERD, and in determining how to 
safely and effectively vaccinate children with any type of HRSV vaccine, is limitations of 
animal models of HRSV infection. The strengths and weaknesses of the different models 
have been reviewed (Bem et al., 2011; Openshaw and Tregoning, 2005). Mouse models of 
HRSV infection and vaccination have been used widely, and they offer unparalleled 
opportunities to manipulate and dissect the immune response. However, because mice are 
not natural hosts of HRSV and are not very permissive to infection, relatively large amounts 
of virus must be administered to cause even mild disease. This may account for the fact that 
vaccination strategies that have appeared promising in mice have often not held up in 
subsequent research using non-human primate models or in human clinical trials. At this 
time it appears that no animal model will perfectly predict safety and efficacy of candidate 
HRSV vaccines. Thus candidate vaccines will always require careful and deliberate stepwise 
testing beginning with immunocompetent adults, then moving to seropositive children, 
then to seronegative children, to seropositive infants, and then to seronegative infants 
(Polack and Karron, 2004; Schickli et al., 2009). This pathway is time consuming, expensive, 
and fraught with the possibility of profound disappointment. Because of this, increased use 
of animal models of natural pneumovirus infection could provide a more efficient and 
fruitful testing ground for screening candidate vaccines and novel vaccination strategies 
before they are tested in non-human primates and in human clinical trials. 
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5. Vaccines for BRSV 
Bovine HRSV and HRSV share many clinical and pathologic similarities in their respective 
hosts. Although no vaccine for human HRSV has yet been approved for use, vaccines for 
BRSV have been marketed since the 1980’s. Because of the similarities between HRSV and 
BRSV, it should be possible to gain insight regarding factors that impact safety, efficacy, and 
duration of immunity in individuals vaccinated either in the presence or absence of 
circulating neutralizing antibodies using the BRSV model. Many published studies have 
shown that commercially available BRSV vaccines can induce protection against 
experimentally induced or naturally occurring BRSV disease (Durham and Hassard, 1990; 
Ellis et al., 2001; Van Donkersgoed et al., 1990b; Vangeel et al., 2007b; Verhoeff and van 
Nieuwstadt, 1984; West et al., 1999b; Xue et al., 2010).  
Like HRSV vaccine ERD, BRSV vaccine ERD following natural BRSV infection has been 
identified; the problem has been associated with both live (Kimman et al., 1989a) and 
inactivated (Schreiber et al., 2000) BRSV vaccines. Kimman et al described a field outbreak of 
BRSV where disease appeared to be enhanced in calves that were vaccinated 
intramuscularly with commercially available modified-live BRSV vaccine while they were in 
an early stage of BRSV infection, as indicated by the retrospective identification of serum 
BRSV-specific IgM in calves at the time they were vaccinated. Disease was clinically evident 
at 1 to 2 weeks post vaccination and was more severe in vaccinated calves than in other 
calves on the farm that were not vaccinated. Schreiber et al described an episode of apparent 
vaccine ERD in calves given a commercially available vaccine inactivated with beta 
propiolactone and adjuvanted with alum and saponin and given by intramuscular injection. 
In an episode of natural BRSV infection that occurred 4 months after the last BRSV 
vaccination was given on this farm, older calves that had not been vaccinated and that had 
lower neutralizing Ab titers had less severe disease than younger calves that had been 
vaccinated and had higher neutralizing Ab titers. Notably, 11 of 35 vaccinated calves died 
during the outbreak, as compared to none of 24 unvaccinated calves. Histopathologic 
evaluation of lung tissue of vaccinated calves that died revealed changes consistent with 
BRSV infection but with infiltration of eosinophils, which are not frequently found in lung 
tissue of calves with severe BRSV disease that is not related to vaccination (Bryson et al., 
1979; Pirie et al., 1981). The identification of eosinophils in lung tissue of calves evaluated in 
the study by Schreiber et al supported the concept that vaccination induced immune 
pathways supporting eosinophil recruitment, possibly related to production TH2 cytokines 
such as IL-5 or release of chemokines such as eotaxin. The incident of vaccine-mediated ERD 
described by Schreiber et al was somewhat unusual in that some of the calves with vaccine 
ERD had higher serum neutralizing Ab titers than unvaccinated calves that had less severe 
disease. This is in contrast to the vaccine ERD induced in children given FI-HRSV in the 
1960’s (Murphy et al., 1986b), and indicates that it is possible for vaccine-induced 
immunopathologic mechanisms to be strong enough to overwhelm protective mechanisms. 
In most studies, inactivated BRSV vaccines induce low levels of neutralizing antibodies 
relative to total BRSV-specific antibody (Ellis et al., 1995; Gershwin et al., 1998).  
The responses of calves vaccinated with FI-BRSV to BRSV challenge have been evaluated by 
at least 4 different groups (Antonis et al., 2003; Gershwin et al., 1998; Mohanty et al., 1981; 
West et al., 1999a). ERD followed challenge in some (Antonis et al., 2003; Gershwin et al., 
1998) but not other (Mohanty et al., 1981; West et al., 1999a) studies. Gershwin’s group 
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showed that the amount of viral protein in the FI-BRSV vaccine was associated with 
induction of vaccine ERD, with vaccine containing relatively smaller amounts of viral 
protein being associated with ERD (Kalina et al., 2005). When FI-BRSV vaccine enhanced 
disease has been identified in cattle, it has been associated with production of high 
concentrations of non-neutralizing antibodies in serum (Gershwin et al., 1998), low levels of 
virus-specific IFN-Ǆ production by PBMCs (Woolums et al., 1999), high concentrations of 
BRSV-specific serum IgE and low concentrations of BRSV-specific IgG1 in lung washes, and 
influx of eosinophils into lung tissue (Antonis et al., 2003; Kalina et al., 2004). These findings 
are consistent with what has been deduced regarding immunopathogensis of FI-HRSV 
vaccination from materials available from children vaccinated in the clinical trials in the 
1960’s, as well as from non-human primate and rodent models of FI-HRSV enhanced 
disease. All together, the extensive literature on BRSV vaccine ERD and similarities to HRSV 
vaccine ERD suggests that the BRSV model is relevant to HRSV vaccine safety. In the bovine 
model, BRSV vaccine ERD and efficacy can be studied in the context of natural infection.  
Although BRSV vaccine ERD has been well-studied, extensive research and clinical 
experience indicate that BRSV vaccination can be safe and effective (Ellis et al., 1995; Ellis et 
al., 2005; Van Donkersgoed et al., 1990a; Vangeel et al., 2007a; Vangeel et al., 2009; Verhoeff 
and van Nieuwstadt, 1984; West et al., 1999b; Xue et al., 2010). In studies of resistance to 
experimental challenge, vaccination of calves with low or absent concentrations of serum 
neutralizing antibodies can protect them from virulent challenge. In a thorough evaluation 
of humoral and cellular immune responses following BRSV challenge of seronegative calves 
vaccinated with commercially available modified live vaccines given by intramuscular 
injection, serum BRSV-specific IgG concentration on days 4 – 7 post challenge and BRSV-
specific IFN-Ǆ production by PBMCs on the day of challenge best predicted protection 
against lung pathology (West et al., 1999b). Nasal fluid concentrations of BRSV-specific IgA 
at day 8 post-challenge were also significantly associated with protection against lung 
pathology, but inclusion of this outcome in the final statistical model did not improve 
prediction of protection. Vaccination with some inactivated vaccines has also provided good 
protection from virulent challenge without disease enhancement, proving that it is possible 
to use inactivated BRSV vaccines safely and effectively (Ellis et al., 1995; Ellis et al., 2005). 
Given the identification of both protection and enhanced disease in calves vaccinated with 
inactivated BRSV vaccines, it is likely that the formulation of the vaccine (as related to 
method of viral inactivation, concentration of viral protein, and nature of adjuvants and 
other components included) is critical to the outcome following BRSV infection of calves 
vaccinated with inactivated vaccines. Other factors such as host genetics and relative 
severity of viral challenge may also be involved.  
Because disease due to BRSV is usually most severe in calves under 6 months of age, 
vaccines administered in the field need to be effective in calves with circulating antibodies 
of maternal origin. This is also true for HRSV vaccines. More research is needed to define 
how calves with maternal antibodies can be most effectively and safely vaccinated against 
BRSV. Work to date indicates that intramuscular (Harmeyer et al., 2006) or intranasal 
(Vangeel et al., 2007a) vaccination with modified live vaccines given to calves with moderate 
to high levels of serum maternal antibodies can be protective as measured by decreased 
severity of clinical signs and/or decreased duration of viral shedding post challenge. A 
small amount of information suggests that modified live but not inactivated vaccine given 
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intranasally may be superior to intramuscular or subcutaneous vaccination in calves with 
maternal antibody (Kimman et al., 1989c). However, modified live intranasal vaccination of 
calves with circulating maternal antibodies did not protect them from disease associated 
with virulent BRSV challenge 4.5 months after vaccination in one study (Ellis et al., 2010). 
The efficacy of vaccination in individuals with maternal antibody likely depends on a 
combination of factors including the nature of vaccine administered, the route of 
administration, the timing and number of doses administered prior to challenge, the 
concentration of serum neutralizing antibodies circulating at the time of vaccination, and the 
severity of challenge, including the titer and virulence of the challenge isolate.  
Clinical trials testing BRSV vaccination efficacy have been described since the 1980’s. Many 
evaluated the impact of BRSV vaccination on all (undifferentiated) respiratory disease; 
fewer have evaluated protection against disease following BRSV infection specifically. In 
trials evaluating the impact of BRSV vaccination on undifferentiated respiratory disease, 
BRSV vaccine included in a panel of vaccines given to at-risk cattle decreased disease in 
some but not all groups of cattle (Van Donkersgoed et al., 1990a). Trials evaluating the 
impact of BRSV vaccination on disease after BRSV infection are more informative about the 
risks and benefits of BRSV vaccination. Most such trials have been carried out in Europe; in 
one excellent example involving 530 calves on 27 farms, calves on farms where all calves 
were vaccinated with a modified live BRSV vaccine by intramuscular route had significantly 
decreased rates of BRSV infection and disease, compared to farms where calves were not 
vaccinated. Farms where half the calves were vaccinated had significantly decreased rates of 
disease but not infection (Verhoeff and van Nieuwstadt, 1984). 
6. Candidate HRSV vaccines 
HRSV vaccine candidates and development have been reviewed thoroughly, so here we 
selectively point out novel strategies (Anderson et al., 2010; Collins and Murphy, 2005; 
Crowe, 2001b; Kneyber and Kimpen, 2004; Moore and Peebles, 2006). Live attenuated 
vaccines have not successfully found a balance of immunogenicity and safety. Adjuvants 
have potential to achieve immunogenicity. CpG oligodeoxynucleotides (CpG ODN, a TLR 9 
agonist) and monophosphoryl lipid (MPL, a TLR 4 agonist) adjuvants enhance immune 
responses to experimental HRSV vaccines (Boukhvalova et al., 2006; Mapletoft et al., 2008; 
Neuzil et al., 1997; Oumouna et al., 2005). A novel oil-in-water nanoemulsion adjuvanted 
inactivated HRSV vaccine showed promise in mice (Lindell et al., 2011). Virus-like particles 
(VLPs) are supramolecular assemblages of antigenic proteins in a repetitive, particulate 
structure (Jennings and Bachmann, 2008). Licensures of two VLP vaccines (papilloma virus 
and hepatitis B virus) reflect the potential of VLP vaccines. Viral proteins presented as VLPs 
are highly immunogenic and induce protective humoral, cellular, and mucosal immune 
responses (Kang et al., 2009; Quan et al., 2007) Recent studies with Venezuelan equine 
encephalitis virus replicon particles (VRPs) expressing HRSV G or F as well as HRSV G-
expressing Newcastle disease VLPs suggest that HRSV nonreplicating VLP-like vaccines, 
even without adjuvants, are immunogenic, effective, and do not cause ERD (Mok et al., 
2007; Murawski et al., 2009). These G- and/or F-expressing VLPs lack immunomodulatory 
NS proteins, so they may less interfere with host immune responses than live attenuated 
vaccines that do express NS proteins. Unfortunately, live attenuated viruses lacking NS 
proteins were over-attenuated (Jin et al., 2003). 
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7. Molecular epidemiology of HRSV 
A better understanding of HRSV molecular epidemiology will be informative for vaccine 
development. HRSV has one serotype, within which there are two antigenic subgroups, A 
and B, defined by reactivity to monoclonal Abs (Collins et al., 2006). Amino acid changes in 
variable regions of the HRSV attachment glycoprotein (G) occur in response to immune 
pressure (Botosso et al., 2009; Cane and Pringle, 1992, 1995; Gaunt et al., 2011; Zlateva et al., 
2005). Within antigenic subgroups, HRSV strains can be further classified into clades, and 
clades can be divided into subtypes based on nt sequence of a hypervariable region of the G 
gene (Cane, 2001; Peret et al., 2000; Peret et al., 1998). The classification of HRSV strains is 
antigenic subgroup > clade > subtype > isolate/strain. Phylogenetic analysis of a hypervariable 
region of the G gene revealed that subgroup A strains can be divided into seven clades 
(GA1-GA7) and subgroup B strains can be divided into four clades (GB1-GB4) (Peret et al., 
2000; Peret et al., 1998). These clades have held up as distinct clusters of circulating HRSV in 
communities around the world, and new clades are being described (Agenbach et al., 2005; 
Botosso et al., 2009; Cane, 2001; Matheson et al., 2006; Parveen et al., 2006; Peret et al., 2000; 
Peret et al., 1998; Scott et al., 2006). HRSV subtypes exhibit >96% nt similarity within 
hypervariable G and thus represent closely related isolates (Peret et al., 1998). Annual HRSV 
epidemics consist of one dominant subtype accounting for approximately 50% of isolates, 
and a variable number of less prevalent subtypes in a small number of clades (Cane, 2001; 
Peret et al., 2000; Peret et al., 1998; Sullender, 2000). The Dominant HRSV subtype in a given 
location is replaced in one or two HRSV seasons (Cane, 2001; Peret et al., 2000; Peret et al., 
1998). Although immune selection appears to drive mutation in the HRSV G protein by 
positive selection, these mutations are not progressive antigenic drift as in influenza 
(Botosso et al., 2009; Cane and Pringle, 1995; Hay et al., 2001). Rather, it appears that 
positively selected sites flip-flop over time (Botosso et al., 2009), suggesting an antigenic 
toggling in G as immunity in the population rises and falls to circulating strains.  
NAbs to HRSV bind either the viral G or F protein (Collins et al., 2006). Responses to HRSV 
F protein are generally cross-neutralizing to diverse HRSV strains whereas Abs to G are 
generally more subgroup- and clade-specific. HRSV induces Abs in humans and mice that 
bind epitopes conserved between all HRSV strains, and these Abs cross-neutralize strains. 
Palivizumab, a monoclonal nAb given prophylactically to humans, binds to the F protein 
and binds all HRSV strains (Meissner and Long, 2003). Despite nAbs that neutralize all 
HRSV strains tested, strain-specific Abs likely contribute to protection. It has been clearly 
demonstrated that the antigenic subgroup (A or B) is important for Ab responses. Ab 
responses to the G protein are largely subgroup-specific whereas Ab responses to the F 
protein are cross-reactive between subgroups A and B (Sullender, 2000; Sullender et al., 
1998). Sera from HRSV antigenic subgroup A strain-infected individuals neutralizes 
subgroup A strains in vitro better than subgroup B strains (Cane, 2001; Sullender, 2000). For 
this reason, bivalent vaccines containing G and/or F proteins from representative subgroup 
A and B strains have been developed and tested in animals (Cheng et al., 2001; Whitehead et 
al., 1999). In addition to subgroup-specific Abs to the G protein, HRSV induces clade- or 
subtype-specific Abs (Beeler and van Wyke, 1989; Johnson et al., 1987; Scott et al., 2007). The 
neutralizing titer (reciprocal of dilution required to inhibit infectivity) of pooled adult 
human HRSV anti-serum varies between 320 and 2,560 for different subgroup A strains 
(Beeler and van Wyke, 1989). This suggests that (G-expressing e.g. live attenuated) vaccines 
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based on one subgroup A strain will induce varied and suboptimal immunity to circulating 
subgroup A strains. Studies have shown that HRSV induces poor nAb titers in infants, and 
< 50% of young infants with culture-documented HRSV infection have detectable nAbs 
(Brandenburg et al., 1997; Wright et al., 2002; Wright et al., 2007). However, these studies 
used one subgroup A strain (A2) as the challenge strain for in vitro neutralization assays.  
8. Conclusion and future directions 
A major goal of studying RSV pathogenesis is to facilitate vaccines by elucidating virus-host 
interactions at the level of immunity and by providing challenge models to test candidate 
vaccines. The pathology of HRSV in infants resembles that of BRSV in calves and PVM in 
mice. The major features of this pathogenesis are 1) viral tropism for airway and alveolar 
epithelial cells, 2) airway epithelial desquamation, 3) obstruction of airways with mixtures 
of mucus, fibrin, and cells (epithelial debris and inflammatory cells), and 4) prominent 
neutrophil and macrophage inflammation in bronchiolar, alveolar, and interstitial spaces. 
Despite limitations, there are tractable non-chimpanzee animal models of HRSV pathogenesis 
that recapitulate key features of this pathogenesis. These include HRSV strain line 19 and 
HRSV clinical isolate infection of BALB/c mice, infection of cotton rats, and infection of 
newborn lambs. Each has advantages and caveats. Robust pathology and pulmonary 
dysfunction are endpoints that could prove useful for vaccine evaluation. Experimental BRSV 
and PVM infection in the natural host provide fully permissive comparative models of HRSV 
pathogenesis. In addition to comparative virology and pathogenesis, the BRSV field parallels 
HRSV with an extensive literature of vaccinology that includes inactivated virus ERD as well 
as numerous successful vaccines. Collaboration in these fields could facilitate insights into 
HRSV vaccines. Challenges such as MatAb, poor immunogenicity, immune modulation, and 
immature neonatal immunity exist in both infants and calves. One difference is that the 
molecular epidemiology of BRSV shows less virus variation than HRSV. Similarly, swine 
influenza exhibits low comparative variation, owing to the fact that these animals are culled, 
so the dynamics of immunity in the population differ from humans. One way to take 
advantage of the BRSV system would be to test HRSV vaccines in calves by challenging with 
chimeric BRSV viruses expressing the HRSV antigen(s). 
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